메뉴 건너뛰기




Volumn , Issue , 2013, Pages 59-95

Vascular targeting approaches to treat cancer

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-CANCER THERAPEUTICS; ANTI-TUMORS; MALIGNANT CELLS; STROMAL CELLS; TUMOR DEVELOPMENT;

EID: 84929689174     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-7876-8_3     Document Type: Chapter
Times cited : (5)

References (191)
  • 2
    • 33644994202 scopus 로고    scopus 로고
    • Vascular targeting: Recent advances and therapeutic perspectives
    • Hajitou A, Pasqualini R, Arap W (2006) Vascular targeting: recent advances and therapeutic perspectives. Trends Cardiovasc Med 16:80-88
    • (2006) Trends Cardiovasc Med , vol.16 , pp. 80-88
    • Hajitou, A.1    Pasqualini, R.2    Arap, W.3
  • 3
    • 0023219734 scopus 로고
    • Transport of molecules in the tumor interstitium: A review
    • Jain RK (1987) Transport of molecules in the tumor interstitium: a review. Cancer Res 47:3039-3051
    • (1987) Cancer Res , vol.47 , pp. 3039-3051
    • Jain, R.K.1
  • 4
    • 0027467414 scopus 로고
    • Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability
    • Folli S, Pèlegrin A, Chalandon Y, Yao X, Buchegger F, Lienard D, Lejeune F, Mach JP (1993) Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 53:829-836
    • (1993) Int J Cancer , vol.53 , pp. 829-836
    • Folli, S.1    Pèlegrin, A.2    Chalandon, Y.3    Yao, X.4    Buchegger, F.5    Lienard, D.6    Lejeune, F.7    Mach, J.P.8
  • 5
    • 85013312416 scopus 로고
    • Tumor angiogenesis: Therapeutic implications
    • Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 7
    • 0035359087 scopus 로고    scopus 로고
    • Molecular addresses in blood vessels as targets for therapy
    • Kolonin MG, Pasqualini R, Arap W (2001) Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 5:308-313
    • (2001) Curr Opin Chem Biol , vol.5 , pp. 308-313
    • Kolonin, M.G.1    Pasqualini, R.2    Arap, W.3
  • 8
    • 16844381577 scopus 로고    scopus 로고
    • A new perspective on tumor endothelial cells: Unexpected chromosome and centrosome abnormalities
    • Hida K, Klagsburn M (2005) A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65:2507-2510
    • (2005) Cancer Res , vol.65 , pp. 2507-2510
    • Hida, K.1    Klagsburn, M.2
  • 9
    • 0002501771 scopus 로고    scopus 로고
    • Antiangiogenic therapy
    • DeVita VT, Hellman S, Rosenberg SA (eds), Lippincott, Philadelphia, PA
    • Folkman J (1997) Antiangiogenic therapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Philadelphia, PA, pp 3075-3085
    • (1997) Cancer: Principles and Practice of Oncology , pp. 3075-3085
    • Folkman, J.1
  • 10
    • 79956328903 scopus 로고    scopus 로고
    • Molecular mechanisms and clinical applications of angiogenesis
    • Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307
    • (2011) Nature , vol.473 , pp. 298-307
    • Carmeliet, P.1    Jain, R.K.2
  • 11
    • 0013943005 scopus 로고
    • Tumour behaviour in isolated perfused organs
    • Folkman J, Cole P, Zimmerman S (1966) Tumour behaviour in isolated perfused organs. Ann Surg 164:491
    • (1966) Ann Surg , vol.164 , pp. 491
    • Folkman, J.1    Cole, P.2    Zimmerman, S.3
  • 12
    • 0014865863 scopus 로고
    • Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumour
    • Tannock IF (1970) Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumour. Cancer Res 30:2470-2477
    • (1970) Cancer Res , vol.30 , pp. 2470-2477
    • Tannock, I.F.1
  • 13
    • 0028789463 scopus 로고
    • Antiangiogenesis as a novel therapeutic concept in pediatric oncology
    • Schweigerer L (1995) Antiangiogenesis as a novel therapeutic concept in pediatric oncology. J Mol Med 73:497-508
    • (1995) J Mol Med , vol.73 , pp. 497-508
    • Schweigerer, L.1
  • 14
    • 0029551759 scopus 로고
    • Microvascular corrosion casting in the study of tumor vascularity: A review
    • Konerding MA, Miodonski AJ, Lametschwandtner A (1995) Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc 9:1233-1244
    • (1995) Scanning Microsc , vol.9 , pp. 1233-1244
    • Konerding, M.A.1    Miodonski, A.J.2    Lametschwandtner, A.3
  • 18
    • 0009504171 scopus 로고    scopus 로고
    • The vascularization of experimental and human primary tumors: Comparative morphometric and morphologic studies
    • Maragoudakis ME (ed), Plenum, New York
    • Konerding MA, Fait E, Gaumann A, Dimitropoulou C, Malkush W (1998) The vascularization of experimental and human primary tumors: comparative morphometric and morphologic studies. In: Maragoudakis ME (ed) Angiogenesis: models modulators and clinical applications. Plenum, New York, pp 429-447
    • (1998) Angiogenesis: Models Modulators and Clinical Applications , pp. 429-447
    • Konerding, M.A.1    Fait, E.2    Gaumann, A.3    Dimitropoulou, C.4    Malkush, W.5
  • 20
    • 0242624629 scopus 로고    scopus 로고
    • Molecular basis of angiogenesis and cancer
    • Tonini T, Rossi F, Claudio PP (2003) Molecular basis of angiogenesis and cancer. Oncogene 22:6549-6556
    • (2003) Oncogene , vol.22 , pp. 6549-6556
    • Tonini, T.1    Rossi, F.2    Claudio, P.P.3
  • 21
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
    • (2000) Nature , vol.407 , pp. 249-257
    • Carmeliet, P.1    Jain, R.K.2
  • 22
    • 1442290142 scopus 로고    scopus 로고
    • Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms
    • Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P (2004) Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 18:338-340
    • (2004) FASEB J , vol.18 , pp. 338-340
    • Erber, R.1    Thurnher, A.2    Katsen, A.D.3    Groth, G.4    Kerger, H.5    Hammes, H.P.6    Menger, M.D.7    Ullrich, A.8    Vajkoczy, P.9
  • 24
    • 0032190614 scopus 로고    scopus 로고
    • Hypoxia-inducible factor 1: Master regulator of O 2 homeostasis
    • Semenza GL (1998) Hypoxia-inducible factor 1: master regulator of O 2 homeostasis. Curr Opin Genet Dev 8:588-594
    • (1998) Curr Opin Genet Dev , vol.8 , pp. 588-594
    • Semenza, G.L.1
  • 25
    • 0015311426 scopus 로고
    • Anti-angiogenesis: New concept for therapy of solid tumors
    • Folkman J (1972) Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175(3):409-416
    • (1972) Ann Surg , vol.175 , Issue.3 , pp. 409-416
    • Folkman, J.1
  • 27
    • 0032530717 scopus 로고    scopus 로고
    • VEGF and the Fab fragment of a humanized neutralizing antibody: Crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface
    • Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM (1998) VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure 6:1153-1167
    • (1998) Structure , vol.6 , pp. 1153-1167
    • Muller, Y.A.1    Chen, Y.2    Christinger, H.W.3    Li, B.4    Cunningham, B.C.5    Lowman, H.B.6    De Vos, A.M.7
  • 28
    • 13444278498 scopus 로고    scopus 로고
    • Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies
    • Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
    • (2005) Cancer Res , vol.65 , pp. 671-680
    • Gerber, H.P.1    Ferrara, N.2
  • 29
    • 0036831559 scopus 로고    scopus 로고
    • Vascular and hematopoietic stem cells: Novel targets for anti-angiogenesis therapy?
    • Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and hematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2:826-835
    • (2002) Nat Rev Cancer , vol.2 , pp. 826-835
    • Rafii, S.1    Lyden, D.2    Benezra, R.3    Hattori, K.4    Heissig, B.5
  • 30
    • 0034796595 scopus 로고    scopus 로고
    • Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
    • Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7:987-989
    • (2001) Nat Med , vol.7 , pp. 987-989
    • Jain, R.K.1
  • 31
    • 11844254414 scopus 로고    scopus 로고
    • Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    • Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
    • (2005) Science , vol.307 , pp. 58-62
    • Jain, R.K.1
  • 32
    • 34748921698 scopus 로고    scopus 로고
    • Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers
    • Duda DG, Jain RK, Willett CG (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033-4042
    • (2007) J Clin Oncol , vol.25 , pp. 4033-4042
    • Duda, D.G.1    Jain, R.K.2    Willett, C.G.3
  • 35
    • 84857424492 scopus 로고    scopus 로고
    • National cancer institute. Online source, Accessed 10 Oct 2012
    • Pazdur R (2011) FDA approval for Bevacizumab. National cancer institute. Online source: http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab. Accessed 10 Oct 2012
    • (2011) FDA Approval for Bevacizumab
    • Pazdur, R.1
  • 38
    • 0035884609 scopus 로고    scopus 로고
    • Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2
    • Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624
    • (2001) Cancer Res , vol.61 , pp. 6624
    • Kunkel, P.1    Ulbricht, U.2    Bohlen, P.3    Brockmann, M.A.4    Fillbrandt, R.5    Stavrou, D.6    Westphal, M.7    Lamszus, K.8
  • 39
    • 0036023438 scopus 로고    scopus 로고
    • Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production
    • Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP (2002) Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8(8):2714-2724
    • (2002) Clin Cancer Res , vol.8 , Issue.8 , pp. 2714-2724
    • Sweeney, P.1    Karashima, T.2    Kim, S.J.3    Kedar, D.4    Mian, B.5    Huang, S.6    Baker, C.7    Fan, Z.8    Hicklin, D.J.9    Pettaway, C.A.10    Dinney, C.P.11
  • 42
    • 85193159780 scopus 로고    scopus 로고
    • Accessed 19 Oct 2012
    • UCB press statement: 01.04.2008: http://www.bionity.com/en/news/80262/ucb-phase-iiresults-for-cdp791-in-non-small-cell-lung-cancer-support-further-clinical-development.html. Accessed 19 Oct 2012
    • UCB Press Statement: 01.04.2008
  • 45
    • 84866370357 scopus 로고    scopus 로고
    • Aflibercept for age-related macular degeneration: A game-changer or quiet addition?
    • Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW (2012) Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154(2):222-226
    • (2012) Am J Ophthalmol , vol.154 , Issue.2 , pp. 222-226
    • Browning, D.J.1    Kaiser, P.K.2    Rosenfeld, P.J.3    Stewart, M.W.4
  • 47
    • 84863011440 scopus 로고    scopus 로고
    • Aflibercept in the treatment of metastatic colorectal cancer
    • Wang TF, Lockhart AC (2012) Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 6:19-30
    • (2012) Clin Med Insights Oncol , vol.6 , pp. 19-30
    • Wang, T.F.1    Lockhart, A.C.2
  • 51
    • 38949178751 scopus 로고    scopus 로고
    • Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KrN951 in a rat peritoneal disseminated tumor model
    • Taguchi E, Nakamura K, Miura T, Shibuya M, Isoe T (2008) Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KrN951 in a rat peritoneal disseminated tumor model. Cancer Sci 99:623-630
    • (2008) Cancer Sci , vol.99 , pp. 623-630
    • Taguchi, E.1    Nakamura, K.2    Miura, T.3    Shibuya, M.4    Isoe, T.5
  • 53
    • 79953236184 scopus 로고    scopus 로고
    • AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer
    • De Gramont A, Van Cutsem E, Tabernero J, Moore MJ, Cunningham D, Rivera F, Im S, Makrutzki M, Shang A, Hoff PM (2011) AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 29(4):362
    • (2011) J Clin Oncol , vol.29 , Issue.4 , pp. 362
    • De Gramont, A.1    Van Cutsem, E.2    Tabernero, J.3    Moore, M.J.4    Cunningham, D.5    Rivera, F.6    Im, S.7    Makrutzki, M.8    Shang, A.9    Hoff, P.M.10
  • 54
    • 47949099628 scopus 로고    scopus 로고
    • Modes of resistance to anti-angiogenic therapy
    • Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
    • (2008) Nat Rev Cancer , vol.8 , pp. 592-603
    • Bergers, G.1    Hanahan, D.2
  • 58
    • 39749166386 scopus 로고    scopus 로고
    • Antiangiogenic therapy for cancer: An update
    • Shojaei F, Ferrara N (2007) Antiangiogenic therapy for cancer: an update. Cancer J 13:345-348
    • (2007) Cancer J , vol.13 , pp. 345-348
    • Shojaei, F.1    Ferrara, N.2
  • 59
    • 35548941394 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC)
    • Kindler HL, Niedzwiecki D, Hollis D, Oraefo E, Schrag D, Hurwitz McLeod HL, Mulcahy MF, Schilsky RL, Goldberg RM (2007) A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC). J Clin Oncol 25:4508
    • (2007) J Clin Oncol , vol.25 , pp. 4508
    • Kindler, H.L.1    Niedzwiecki, D.2    Hollis, D.3    Oraefo, E.4    Schrag, D.5    Hurwitz McLeod, H.L.6    Mulcahy, M.F.7    Schilsky, R.L.8    Goldberg, R.M.9
  • 60
    • 0035692285 scopus 로고    scopus 로고
    • Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches
    • Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J (2001) Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 20:79-86
    • (2001) Cancer Metastasis Rev , vol.20 , pp. 79-86
    • Kerbel, R.S.1    Yu, J.2    Tran, J.3    Man, S.4    Viloria-Petit, A.5    Klement, G.6    Coomber, B.L.7    Rak, J.8
  • 61
    • 26644471951 scopus 로고    scopus 로고
    • Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    • Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309
    • (2005) Cancer Cell , vol.8 , pp. 299-309
    • Casanovas, O.1    Hicklin, D.J.2    Bergers, G.3    Hanahan, D.4
  • 62
    • 80051690789 scopus 로고    scopus 로고
    • Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition
    • Allen E, Walters IB, Hanahan D (2011) Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res 17:5299
    • (2011) Clin Cancer Res , vol.17 , pp. 5299
    • Allen, E.1    Walters, I.B.2    Hanahan, D.3
  • 64
    • 40949148520 scopus 로고    scopus 로고
    • Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors
    • Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, Ryeom S, Yoon SS (2008) Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 14:1529-1539
    • (2008) Clin Cancer Res , vol.14 , pp. 1529-1539
    • Fernando, N.T.1    Koch, M.2    Rothrock, C.3    Gollogly, L.K.4    D'amore, P.A.5    Ryeom, S.6    Yoon, S.S.7
  • 67
    • 0038476608 scopus 로고    scopus 로고
    • Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    • Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295
    • (2003) J Clin Invest , vol.111 , pp. 1287-1295
    • Bergers, G.1    Song, S.2    Meyer-Morse, N.3    Bergsland, E.4    Hanahan, D.5
  • 68
    • 0346727319 scopus 로고    scopus 로고
    • What brings pericytes to tumor vessels?
    • Jain RK, Booth MF (2003) What brings pericytes to tumor vessels? J Clin Invest 112:1134-1136
    • (2003) J Clin Invest , vol.112 , pp. 1134-1136
    • Jain, R.K.1    Booth, M.F.2
  • 69
    • 0031834239 scopus 로고    scopus 로고
    • A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
    • Benjamin L, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598
    • (1998) Development , vol.125 , pp. 1591-1598
    • Benjamin, L.1    Hemo, I.2    Keshet, E.3
  • 70
    • 0033822622 scopus 로고    scopus 로고
    • Anti- VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
    • Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA (2000) Anti- VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306-314
    • (2000) Neoplasia , vol.2 , pp. 306-314
    • Rubenstein, J.L.1    Kim, J.2    Ozawa, T.3    Zhang, M.4    Westphal, M.5    Deen, D.F.6    Shuman, M.A.7
  • 75
    • 68049139572 scopus 로고    scopus 로고
    • Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells
    • Xiong YQ, Sun HC, Zhang W, Zhu XD, Zhuang PY, Zhang JB, Wang L, Wu WZ, Qin LX, Tang ZY (2009) Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15:4838
    • (2009) Clin Cancer Res , vol.15 , pp. 4838
    • Xiong, Y.Q.1    Sun, H.C.2    Zhang, W.3    Zhu, X.D.4    Zhuang, P.Y.5    Zhang, J.B.6    Wang, L.7    Wu, W.Z.8    Qin, L.X.9    Tang, Z.Y.10
  • 78
    • 84857995039 scopus 로고    scopus 로고
    • Predictive in vivo animal models and translation to clinical trials
    • Cook N, Jodrell DI, Tuveson DA (2012) Predictive in vivo animal models and translation to clinical trials. Drug Discov Today 17(5-6):253-260
    • (2012) Drug Discov Today , vol.17 , Issue.5-6 , pp. 253-260
    • Cook, N.1    Jodrell, D.I.2    Tuveson, D.A.3
  • 80
    • 0000742387 scopus 로고
    • A critique of tumour resistance
    • Woglam WH (1923) A critique of tumour resistance. J Cancer Res 7:283-311
    • (1923) J Cancer Res , vol.7 , pp. 283-311
    • Woglam, W.H.1
  • 82
    • 0020081554 scopus 로고
    • Endothelial cell proliferation as a novel approach to targeting tumour therapy
    • Denekamp J (1982) Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 45:136-139
    • (1982) Br J Cancer , vol.45 , pp. 136-139
    • Denekamp, J.1
  • 83
    • 0020449692 scopus 로고
    • Endothelial-cell proliferation in experimental tumours
    • Denekamp J, Hobson B (1982) Endothelial-cell proliferation in experimental tumours. Br J Cancer 46(5):711-720
    • (1982) Br J Cancer , vol.46 , Issue.5 , pp. 711-720
    • Denekamp, J.1    Hobson, B.2
  • 84
    • 0025093973 scopus 로고
    • Vascular attack as a therapeutic strategy for cancer
    • Denekamp J (1990) Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev 9:267-282
    • (1990) Cancer Metastasis Rev , vol.9 , pp. 267-282
    • Denekamp, J.1
  • 86
    • 0025793698 scopus 로고
    • Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
    • Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27:482-487
    • (1991) Eur J Cancer , vol.27 , pp. 482-487
    • Baguley, B.C.1    Holdaway, K.M.2    Thomsen, L.L.3    Zhuang, L.4    Zwi, L.J.5
  • 87
    • 0030951899 scopus 로고    scopus 로고
    • Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature
    • Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57:1829-1834
    • (1997) Cancer Res , vol.57 , pp. 1829-1834
    • Dark, G.G.1    Hill, S.A.2    Prise, V.E.3    Tozer, G.M.4    Pettit, G.R.5    Chaplin, D.J.6
  • 88
    • 0031748452 scopus 로고    scopus 로고
    • Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
    • Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM (1998) Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 77:1761-1767
    • (1998) Br J Cancer , vol.77 , pp. 1761-1767
    • Beauregard, D.A.1    Thelwall, P.E.2    Chaplin, D.J.3    Hill, S.A.4    Adams, G.E.5    Brindle, K.M.6
  • 89
    • 0031770618 scopus 로고    scopus 로고
    • The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors
    • Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J (1998) The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 42(4):895-898
    • (1998) Int J Radiat Oncol Biol Phys , vol.42 , Issue.4 , pp. 895-898
    • Horsman, M.R.1    Ehrnrooth, E.2    Ladekarl, M.3    Overgaard, J.4
  • 90
    • 0034906627 scopus 로고    scopus 로고
    • Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model
    • Malcontenti-Wilson C, Muralidharan V, Skinner S, Christophi C, Sherris D, O'Brien PE (2001) Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin Cancer Res 7(4):1052-1060
    • (2001) Clin Cancer Res , vol.7 , Issue.4 , pp. 1052-1060
    • Malcontenti-Wilson, C.1    Muralidharan, V.2    Skinner, S.3    Christophi, C.4    Sherris, D.5    O'brien, P.E.6
  • 97
    • 0032729686 scopus 로고    scopus 로고
    • Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700
    • Hori K, Saito S, Nihei Y, Suzuki M, Sato Y (1999) Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 90:1026-1038
    • (1999) Jpn J Cancer Res , vol.90 , pp. 1026-1038
    • Hori, K.1    Saito, S.2    Nihei, Y.3    Suzuki, M.4    Sato, Y.5
  • 98
    • 0035146174 scopus 로고    scopus 로고
    • Stoppage of blood flow in 3-methylcholanthreneinduced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect
    • Hori K, Saito S, Sato Y, Kubota K (2001) Stoppage of blood flow in 3-methylcholanthreneinduced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit 7:26-33
    • (2001) Med Sci Monit , vol.7 , pp. 26-33
    • Hori, K.1    Saito, S.2    Sato, Y.3    Kubota, K.4
  • 99
    • 0037141466 scopus 로고    scopus 로고
    • A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
    • Hori K, Saito S, Kubota K (2002) A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer 86:1604-1614
    • (2002) Br J Cancer , vol.86 , pp. 1604-1614
    • Hori, K.1    Saito, S.2    Kubota, K.3
  • 100
    • 0035985910 scopus 로고    scopus 로고
    • Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer
    • Ohno T, Kawano K, Sasaki A, Aramaki M, Tahara K, Etoh T, Kitano S (2002) Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int J Clin Oncol 7:171-176
    • (2002) Int J Clin Oncol , vol.7 , pp. 171-176
    • Ohno, T.1    Kawano, K.2    Sasaki, A.3    Aramaki, M.4    Tahara, K.5    Etoh, T.6    Kitano, S.7
  • 101
    • 84879554909 scopus 로고    scopus 로고
    • The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
    • Clémenson C, Jouannot E, Merino-Trigo A, Rubin-Carrez C, Deutsch E (2012) The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models. Invest New Drugs 31(2):273-284
    • (2012) Invest New Drugs , vol.31 , Issue.2 , pp. 273-284
    • Clémenson, C.1    Jouannot, E.2    Merino-Trigo, A.3    Rubin-Carrez, C.4    Deutsch, E.5
  • 102
    • 0034530967 scopus 로고    scopus 로고
    • Cadherins as modulators of angiogenesis and the structural integrity of blood vessels
    • Blaschuk OW, Rowlands TM (2000) Cadherins as modulators of angiogenesis and the structural integrity of blood vessels. Cancer Metastasis Rev 19:1-5
    • (2000) Cancer Metastasis Rev , vol.19 , pp. 1-5
    • Blaschuk, O.W.1    Rowlands, T.M.2
  • 103
    • 58149492762 scopus 로고    scopus 로고
    • Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player
    • Vestweber D, Winderlich M, Cagna G, Nottebaum AF (2009) Cell adhesion dynamics at endothelial junctions: VE-cadherin as a major player. Trends Cell Biol 19:8-15
    • (2009) Trends Cell Biol , vol.19 , pp. 8-15
    • Vestweber, D.1    Winderlich, M.2    Cagna, G.3    Nottebaum, A.F.4
  • 104
    • 33947302866 scopus 로고    scopus 로고
    • Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization
    • Kelland L (2007) Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization. Curr Opin Mol Ther 9:86-91
    • (2007) Curr Opin Mol Ther , vol.9 , pp. 86-91
    • Kelland, L.1
  • 105
    • 34247096609 scopus 로고    scopus 로고
    • ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer
    • Li H, Price DK, Figg WD (2007) ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs 18:563-568
    • (2007) Anticancer Drugs , vol.18 , pp. 563-568
    • Li, H.1    Price, D.K.2    Figg, W.D.3
  • 108
  • 110
    • 0037112419 scopus 로고    scopus 로고
    • High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow
    • Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS (2002) High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Res 62:6371-6375
    • (2002) Cancer Res , vol.62 , pp. 6371-6375
    • Goertz, D.E.1    Yu, J.L.2    Kerbel, R.S.3    Burns, P.N.4    Foster, F.S.5
  • 112
    • 0036891109 scopus 로고    scopus 로고
    • Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126
    • Siemann DW, Rojiani AM (2002) Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 54:1512-1517
    • (2002) Int J Radiat Oncol Biol Phys , vol.54 , pp. 1512-1517
    • Siemann, D.W.1    Rojiani, A.M.2
  • 113
    • 0036644835 scopus 로고    scopus 로고
    • Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice
    • Goto H, Yano S, Zhang H, Matsumori Y, Ogawa H, Blakey DC, Sone S (2002) Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 62:3711-3715
    • (2002) Cancer Res , vol.62 , pp. 3711-3715
    • Goto, H.1    Yano, S.2    Zhang, H.3    Matsumori, Y.4    Ogawa, H.5    Blakey, D.C.6    Sone, S.7
  • 114
    • 33845286942 scopus 로고    scopus 로고
    • Vascular disrupting agents
    • Lippert JW III (2007) Vascular disrupting agents. Bioorg Med Chem 15(2):605-615
    • (2007) Bioorg Med Chem , vol.15 , Issue.2 , pp. 605-615
    • Lippert Iii, J.W.1
  • 116
    • 0842311621 scopus 로고    scopus 로고
    • Vascular targeting agents as cancer therapeutics
    • Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427
    • (2004) Clin Cancer Res , vol.10 , pp. 415-427
    • Thorpe, P.E.1
  • 117
    • 0027368441 scopus 로고
    • Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature
    • Burrows FJ, Thorpe PE (1993) Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90:8996-9000
    • (1993) Proc Natl Acad Sci USA , vol.90 , pp. 8996-9000
    • Burrows, F.J.1    Thorpe, P.E.2
  • 118
    • 0024594936 scopus 로고
    • A tumorassociated fibronectin isoform generated by alternative splicing of messenger RNA precursors
    • Carnemolla B, Baiza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natalie PG (1989) A tumorassociated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 108:1139-1148
    • (1989) J Cell Biol , vol.108 , pp. 1139-1148
    • Carnemolla, B.1    Baiza, E.2    Siri, A.3    Zardi, L.4    Nicotra, M.R.5    Bigotti, A.6    Natalie, P.G.7
  • 119
    • 0029802551 scopus 로고    scopus 로고
    • Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain
    • Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L (1996) Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 68(3):397-405
    • (1996) Int J Cancer , vol.68 , Issue.3 , pp. 397-405
    • Carnemolla, B.1    Neri, D.2    Castellani, P.3    Leprini, A.4    Neri, G.5    Pini, A.6    Winter, G.7    Zardi, L.8
  • 120
    • 0036841992 scopus 로고    scopus 로고
    • Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin
    • Castellani P, Borsi L, Carnemolla B, Birò A, Dorcaratto A, Viale GL, Neri D, Zardi L (2002) Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 161(5):1695-1700
    • (2002) Am J Pathol , vol.161 , Issue.5 , pp. 1695-1700
    • Castellani, P.1    Borsi, L.2    Carnemolla, B.3    Birò, A.4    Dorcaratto, A.5    Viale, G.L.6    Neri, D.7    Zardi, L.8
  • 123
    • 70249129332 scopus 로고    scopus 로고
    • Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma
    • Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W, Neri D (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res 33(12):1718-1722
    • (2009) Leuk Res , vol.33 , Issue.12 , pp. 1718-1722
    • Schliemann, C.1    Wiedmer, A.2    Pedretti, M.3    Szczepanowski, M.4    Klapper, W.5    Neri, D.6
  • 125
    • 0036603896 scopus 로고    scopus 로고
    • In vivo phage display and vascular heterogeneity: Implications for targeted medicine
    • Trepel M, Arap W, Pasqualini R (2002) In vivo phage display and vascular heterogeneity: implications for targeted medicine. Curr Opin Chem Biol 6:399-404
    • (2002) Curr Opin Chem Biol , vol.6 , pp. 399-404
    • Trepel, M.1    Arap, W.2    Pasqualini, R.3
  • 127
    • 0037133279 scopus 로고    scopus 로고
    • Molecular specialization of breast vasculature: A breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature
    • Essler M, Ruoslahti E (2002) Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci U S A 99(4):2252-2257
    • (2002) Proc Natl Acad Sci U S A , vol.99 , Issue.4 , pp. 2252-2257
    • Essler, M.1    Ruoslahti, E.2
  • 128
    • 33846014642 scopus 로고    scopus 로고
    • Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection
    • Ruan W, Sassoon A, An F, Simko JP, Liu B (2006) Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics 5(12):2364-2373
    • (2006) Mol Cell Proteomics , vol.5 , Issue.12 , pp. 2364-2373
    • Ruan, W.1    Sassoon, A.2    An, F.3    Simko, J.P.4    Liu, B.5
  • 129
    • 1942424256 scopus 로고    scopus 로고
    • Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries
    • Mutuberria R, Satijn S, Huijbers A, Van Der Linden E, Lichtenbeld H, Chames P, Arends JW, Hoogenboom HR (2004) Isolation of human antibodies to tumor-associated endothelial cell markers by in vitro human endothelial cell selection with phage display libraries. J Immunol Methods 287(1-2):31-47
    • (2004) J Immunol Methods , vol.287 , Issue.1-2 , pp. 31-47
    • Mutuberria, R.1    Satijn, S.2    Huijbers, A.3    Van Der Linden, E.4    Lichtenbeld, H.5    Chames, P.6    Arends, J.W.7    Hoogenboom, H.R.8
  • 131
    • 0000403288 scopus 로고    scopus 로고
    • Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays
    • Zhang HT, Gorn M, Smith K, Graham AP, Lau KK, Bicknell R (1999) Transcriptional profiling of human microvascular endothelial cells in the proliferative and quiescent state using cDNA arrays. Angiogenesis 3(3):211-219
    • (1999) Angiogenesis , vol.3 , Issue.3 , pp. 211-219
    • Zhang, H.T.1    Gorn, M.2    Smith, K.3    Graham, A.P.4    Lau, K.K.5    Bicknell, R.6
  • 133
    • 44649110229 scopus 로고    scopus 로고
    • Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium
    • Ghilardi C, Chiorino G, Dossi R, Nagy Z, Giavazzi R, Bani MR (2008) Identification of novel vascular markers through gene expression profiling of tumor-derived endothelium. BMC Genomics 9:201
    • (2008) BMC Genomics , vol.9 , pp. 201
    • Ghilardi, C.1    Chiorino, G.2    Dossi, R.3    Nagy, Z.4    Giavazzi, R.5    Bani, M.R.6
  • 134
    • 0033669849 scopus 로고    scopus 로고
    • In silico cloning of novel endothelial-specific genes
    • Huminiecki L, Bicknell R (2000) In silico cloning of novel endothelial-specific genes. Genome Res 10(11):1796-1806
    • (2000) Genome Res , vol.10 , Issue.11 , pp. 1796-1806
    • Huminiecki, L.1    Bicknell, R.2
  • 135
    • 0036209165 scopus 로고    scopus 로고
    • Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis
    • Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R (2002) Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics 79(4):547-552
    • (2002) Genomics , vol.79 , Issue.4 , pp. 547-552
    • Huminiecki, L.1    Gorn, M.2    Suchting, S.3    Poulsom, R.4    Bicknell, R.5
  • 136
    • 0344443678 scopus 로고    scopus 로고
    • EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor
    • Sullivan DC, Huminiecki L, Moore JW, Boyle JJ, Poulsom R, Creamer D, Barker J, Bicknell R (2003) EndoPDI, a novel protein-disulfide isomerase-like protein that is preferentially expressed in endothelial cells acts as a stress survival factor. J Biol Chem 278:47079-47088
    • (2003) J Biol Chem , vol.278 , pp. 47079-47088
    • Sullivan, D.C.1    Huminiecki, L.2    Moore, J.W.3    Boyle, J.J.4    Poulsom, R.5    Creamer, D.6    Barker, J.7    Bicknell, R.8
  • 137
    • 42949106096 scopus 로고    scopus 로고
    • A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes
    • Herbert JMJ, Stekel D, Sanderson S, Heath VL, Bicknell R (2008) A novel method of differential gene expression analysis using multiple cDNA libraries applied to the identification of tumour endothelial genes. BMC Genomics 9:153
    • (2008) BMC Genomics , vol.9 , pp. 153
    • Herbert, J.M.J.1    Stekel, D.2    Sanderson, S.3    Heath, V.L.4    Bicknell, R.5
  • 138
    • 2942529235 scopus 로고    scopus 로고
    • Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy
    • Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, Testa JE, Schnitzer JE (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429(6992):629-635
    • (2004) Nature , vol.429 , Issue.6992 , pp. 629-635
    • Oh, P.1    Li, Y.2    Yu, J.3    Durr, E.4    Krasinska, K.M.5    Carver, L.A.6    Testa, J.E.7    Schnitzer, J.E.8
  • 139
    • 18744399322 scopus 로고    scopus 로고
    • In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature
    • Rybak JN, Ettorre A, Kaissling B, Giavazzi R, Neri D, Elia G (2005) In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods 2(4):291-298
    • (2005) Nat Methods , vol.2 , Issue.4 , pp. 291-298
    • Rybak, J.N.1    Ettorre, A.2    Kaissling, B.3    Giavazzi, R.4    Neri, D.5    Elia, G.6
  • 140
    • 33751416666 scopus 로고    scopus 로고
    • A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer
    • Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, Rybak JN, Neri D (2006) A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 5(11):2083-2091
    • (2006) Mol Cell Proteomics , vol.5 , Issue.11 , pp. 2083-2091
    • Castronovo, V.1    Waltregny, D.2    Kischel, P.3    Roesli, C.4    Elia, G.5    Rybak, J.N.6    Neri, D.7
  • 141
    • 57349106602 scopus 로고    scopus 로고
    • Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis
    • Conrotto P, Roesli C, Rybak J, Kischel P, Waltregny D, Neri D, Castronovo V (2008) Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer 123(12):2856-2864
    • (2008) Int J Cancer , vol.123 , Issue.12 , pp. 2856-2864
    • Conrotto, P.1    Roesli, C.2    Rybak, J.3    Kischel, P.4    Waltregny, D.5    Neri, D.6    Castronovo, V.7
  • 143
    • 0031026481 scopus 로고    scopus 로고
    • Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
    • Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275:547-550
    • (1997) Science , vol.275 , pp. 547-550
    • Huang, X.1    Molema, G.2    King, S.3    Watkins, L.4    Edgington, T.S.5    Thorpe, P.E.6
  • 144
    • 0032532656 scopus 로고    scopus 로고
    • Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature
    • Ran S, Gao B, Duffy S, Watkins L, Rote N, Thorpe PE (1998) Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res 58:4646-4653
    • (1998) Cancer Res , vol.58 , pp. 4646-4653
    • Ran, S.1    Gao, B.2    Duffy, S.3    Watkins, L.4    Rote, N.5    Thorpe, P.E.6
  • 145
    • 0035863566 scopus 로고    scopus 로고
    • Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice
    • Nilsson F, Kosmehl H, Zardi L, Neri D (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61:711-716
    • (2001) Cancer Res , vol.61 , pp. 711-716
    • Nilsson, F.1    Kosmehl, H.2    Zardi, L.3    Neri, D.4
  • 147
    • 0032943892 scopus 로고    scopus 로고
    • Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
    • Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS (1999) Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 59:183-188
    • (1999) Cancer Res , vol.59 , pp. 183-188
    • Arora, N.1    Masood, R.2    Zheng, T.3    Cai, J.4    Smith, D.L.5    Gill, P.S.6
  • 148
    • 0029915612 scopus 로고    scopus 로고
    • Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo
    • Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D (1996) Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56:1324-1330
    • (1996) Cancer Res , vol.56 , pp. 1324-1330
    • Ramakrishnan, S.1    Olson, T.A.2    Bautch, V.L.3    Mohanraj, D.4
  • 150
    • 0036493867 scopus 로고    scopus 로고
    • Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
    • Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99(5):1659-1665
    • (2002) Blood , vol.99 , Issue.5 , pp. 1659-1665
    • Carnemolla, B.1    Borsi, L.2    Balza, E.3    Castellani, P.4    Meazza, R.5    Berndt, A.6    Ferrini, S.7    Kosmehl, H.8    Neri, D.9    Zardi, L.10
  • 151
    • 33748866249 scopus 로고    scopus 로고
    • An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties
    • Gafner V, Trachsel E, Neri D (2006) An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer 119(9):2205-2212
    • (2006) Int J Cancer , vol.119 , Issue.9 , pp. 2205-2212
    • Gafner, V.1    Trachsel, E.2    Neri, D.3
  • 152
    • 42549099073 scopus 로고    scopus 로고
    • A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo
    • Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, Rybak JN, Rösli C, Borsi L, Neri D (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122(11):2405-2413
    • (2008) Int J Cancer , vol.122 , Issue.11 , pp. 2405-2413
    • Villa, A.1    Trachsel, E.2    Kaspar, M.3    Schliemann, C.4    Sommavilla, R.5    Rybak, J.N.6    Rösli, C.7    Borsi, L.8    Neri, D.9
  • 153
    • 0037404842 scopus 로고    scopus 로고
    • Endoglin (CD105): A target for antiangiogenetic cancer therapy
    • Fonsatti E, Altomonte M, Arslan P, Maio M (2003) Endoglin (CD105): a target for antiangiogenetic cancer therapy. Curr Drug Targets 4(4):291-296
    • (2003) Curr Drug Targets , vol.4 , Issue.4 , pp. 291-296
    • Fonsatti, E.1    Altomonte, M.2    Arslan, P.3    Maio, M.4
  • 154
    • 33744811140 scopus 로고    scopus 로고
    • Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C
    • Brack SS, Silacci M, Birchler M, Neri D (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 12(10):3200-3208
    • (2006) Clin Cancer Res , vol.12 , Issue.10 , pp. 3200-3208
    • Brack, S.S.1    Silacci, M.2    Birchler, M.3    Neri, D.4
  • 155
    • 37649010802 scopus 로고    scopus 로고
    • Clinical experience with alpha-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
    • Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD (2007) Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 49(1):30-38
    • (2007) J Nucl Med , vol.49 , Issue.1 , pp. 30-38
    • Zalutsky, M.R.1    Reardon, D.A.2    Akabani, G.3    Coleman, R.E.4    Friedman, A.H.5    Friedman, H.S.6    McLendon, R.E.7    Wong, T.Z.8    Bigner, D.D.9
  • 158
    • 57749090308 scopus 로고    scopus 로고
    • Integrin αvβ3-targeted cancer therapy
    • Liu Z, Wang F, Chen X (2008) Integrin αvβ3-targeted cancer therapy. Drug Dev Res 69(6):329-339
    • (2008) Drug Dev Res , vol.69 , Issue.6 , pp. 329-339
    • Liu, Z.1    Wang, F.2    Chen, X.3
  • 161
    • 14644430393 scopus 로고    scopus 로고
    • Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice
    • Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE (2005) Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res 11:1551-1562
    • (2005) Clin Cancer Res , vol.11 , pp. 1551-1562
    • Ran, S.1    He, J.2    Huang, X.3    Soares, M.4    Scothorn, D.5    Thorpe, P.E.6
  • 162
    • 0033529314 scopus 로고    scopus 로고
    • Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model
    • Hu Z, Sun Y, Garen A (1999) Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci U S A 96(14):8161-8166
    • (1999) Proc Natl Acad Sci U S A , vol.96 , Issue.14 , pp. 8161-8166
    • Hu, Z.1    Sun, Y.2    Garen, A.3
  • 163
    • 77649185057 scopus 로고    scopus 로고
    • Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies
    • Zhang YF, Wang J, Bian D, Zhang X, Zhang Q (2010) Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 74(3):467-473
    • (2010) Eur J Pharm Biopharm , vol.74 , Issue.3 , pp. 467-473
    • Zhang, Y.F.1    Wang, J.2    Bian, D.3    Zhang, X.4    Zhang, Q.5
  • 165
    • 14944353793 scopus 로고    scopus 로고
    • Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs
    • Corti A, Ponzoni M (2004) Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs. Ann N Y Acad Sci 1028:104-112
    • (2004) Ann N y Acad Sci , vol.1028 , pp. 104-112
    • Corti, A.1    Ponzoni, M.2
  • 166
    • 0038124364 scopus 로고    scopus 로고
    • Targeted delivery of mutant Raf kinase to neovessels causes tumor regression
    • Hood JD, Cheresh DA (2002) Targeted delivery of mutant Raf kinase to neovessels causes tumor regression. Cold Spring Harb Symp Quant Biol 67:285-292
    • (2002) Cold Spring Harb Symp Quant Biol , vol.67 , pp. 285-292
    • Hood, J.D.1    Cheresh, D.A.2
  • 168
    • 33747122052 scopus 로고    scopus 로고
    • Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature
    • Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA (2006) Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47(7):1127-1135
    • (2006) J Nucl Med , vol.47 , Issue.7 , pp. 1127-1135
    • Tijink, B.M.1    Neri, D.2    Leemans, C.R.3    Budde, M.4    Dinkelborg, L.M.5    Stigter-Van Walsum, M.6    Zardi, L.7    Van Dongen, G.A.8
  • 170
    • 0032697129 scopus 로고    scopus 로고
    • Radioimmunotherapy using vascular targeted 213Bi: The role of tumor necrosis factor alpha in the development of pulmonary fibrosis
    • Davis IA, Kennel SJ (1999) Radioimmunotherapy using vascular targeted 213Bi: the role of tumor necrosis factor alpha in the development of pulmonary fibrosis. Clin Cancer Res 5(10):3160-3164
    • (1999) Clin Cancer Res , vol.5 , Issue.10 , pp. 3160-3164
    • Davis, I.A.1    Kennel, S.J.2
  • 171
    • 74049132050 scopus 로고    scopus 로고
    • First-line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT-phase II study
    • Löhr M, Haas S, Bechstein W, Karrasch M, Mescheder A, Meyer I, Bodoky G, Pap A, Jäger D, Fölsch UR (2008) First-line treatment of inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT-phase II study. J Clin Oncol 26:2008
    • (2008) J Clin Oncol , vol.26 , pp. 2008
    • Löhr, M.1    Haas, S.2    Bechstein, W.3    Karrasch, M.4    Mescheder, A.5    Meyer, I.6    Bodoky, G.7    Pap, A.8    Jäger, D.9    Fölsch, U.R.10
  • 172
    • 85193166823 scopus 로고    scopus 로고
    • Accessed 2 Oct 2012
    • Medigene press statement: http://www.medigene.com/products-pipeline/developmentprojects/endotag-1. Accessed 2 Oct 2012
    • Medigene Press Statement
  • 173
    • 51049100187 scopus 로고    scopus 로고
    • The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer
    • Wagner K, Schulz P, Scholz A, Wiedenmann B, Menrad A (2008) The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res 14(15):4951-4960
    • (2008) Clin Cancer Res , vol.14 , Issue.15 , pp. 4951-4960
    • Wagner, K.1    Schulz, P.2    Scholz, A.3    Wiedenmann, B.4    Menrad, A.5
  • 175
  • 176
    • 84918804807 scopus 로고    scopus 로고
    • Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patients
    • Weide B, Eigentler TK, Romanini A, De Braud FG, Giovannoni L, Neri D, Menssen H, Garbe C (2010) Tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patients. J Clin Oncol 28:15s
    • (2010) J Clin Oncol , vol.28 , pp. 15s
    • Weide, B.1    Eigentler, T.K.2    Romanini, A.3    De Braud, F.G.4    Giovannoni, L.5    Neri, D.6    Menssen, H.7    Garbe, C.8
  • 179
    • 0036204508 scopus 로고    scopus 로고
    • Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor-immunotoxin target gene
    • Jin N, Chen W, Blazar BR, Ramakrishnan S, Vallera DA (2002) Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor-immunotoxin target gene. Hum Gene Ther 13:497-508
    • (2002) Hum Gene Ther , vol.13 , pp. 497-508
    • Jin, N.1    Chen, W.2    Blazar, B.R.3    Ramakrishnan, S.4    Vallera, D.A.5
  • 180
    • 84864812720 scopus 로고    scopus 로고
    • Antiangiogenic tumor therapy by DNA vaccine inducing aquaporin-1-specific CTL based on ubiquitin-proteasome system in mice
    • Chou B, Hiromatsu K, Okano S, Ishii K, Duan X, Sakai T, Murata S, Tanaka K, Himeno K (2012) Antiangiogenic tumor therapy by DNA vaccine inducing aquaporin-1-specific CTL based on ubiquitin-proteasome system in mice. J Immunol 189(4):1618-1626
    • (2012) J Immunol , vol.189 , Issue.4 , pp. 1618-1626
    • Chou, B.1    Hiromatsu, K.2    Okano, S.3    Ishii, K.4    Duan, X.5    Sakai, T.6    Murata, S.7    Tanaka, K.8    Himeno, K.9
  • 181
    • 2642571660 scopus 로고    scopus 로고
    • Vascular-targeting therapies for treatment of malignant disease
    • Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100(12):2491-2499
    • (2004) Cancer , vol.100 , Issue.12 , pp. 2491-2499
    • Siemann, D.W.1    Chaplin, D.J.2    Horsman, M.R.3
  • 182
    • 1842689545 scopus 로고    scopus 로고
    • Targeting the tumor vasculature: A strategy to improve radiation therapy
    • Siemann DW, Horsman MR (2004) Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Rev Anticancer Ther 4(2):321-327
    • (2004) Expert Rev Anticancer Ther , vol.4 , Issue.2 , pp. 321-327
    • Siemann, D.W.1    Horsman, M.R.2
  • 183
    • 14644446018 scopus 로고    scopus 로고
    • A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
    • Pietras K, Hanahan D (2005) A multitargeted, metronomic, and maximum-tolerated dose 'chemo-switch' regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23(5):939-952
    • (2005) J Clin Oncol , vol.23 , Issue.5 , pp. 939-952
    • Pietras, K.1    Hanahan, D.2
  • 185
    • 0033881435 scopus 로고    scopus 로고
    • Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma
    • Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ (2000) Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 60(15):4066-4069
    • (2000) Cancer Res , vol.60 , Issue.15 , pp. 4066-4069
    • Ferrario, A.1    Von Tiehl, K.F.2    Rucker, N.3    Schwarz, M.A.4    Gill, P.S.5    Gomer, C.J.6
  • 186
    • 7444259131 scopus 로고    scopus 로고
    • Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors
    • Siemann DW, Shi W (2004) Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors. Int J Radiat Oncol Biol Phys 60(4):1233-1240
    • (2004) Int J Radiat Oncol Biol Phys , vol.60 , Issue.4 , pp. 1233-1240
    • Siemann, D.W.1    Shi, W.2
  • 187
    • 27744553032 scopus 로고    scopus 로고
    • Targeting the tumor vasculature: Enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474
    • Shi W, Siemann DW (2005) Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 19(6):1045-1050
    • (2005) Vivo , vol.19 , Issue.6 , pp. 1045-1050
    • Shi, W.1    Siemann, D.W.2
  • 188
    • 49049086508 scopus 로고    scopus 로고
    • Dual targeting of tumor vasculature: Combining Avastin and vascular disrupting agents (CA4P or OXi4503
    • Siemann DW, Shi W (2008) Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 28(4B):2027-2031
    • (2008) Anticancer Res , vol.28 B , Issue.4 , pp. 2027-2031
    • Siemann, D.W.1    Shi, W.2
  • 190
    • 84859606443 scopus 로고    scopus 로고
    • A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): Analysis of safety and activity of the FALCON trial
    • Garon EB, Kabbinavar FF, Neidhart JA, Neidhart JD, Gabrail NY, Oliveira MR, Lu S, Balkissoon J (2011) A randomized phase II trial of a vascular disrupting agent (VDA) fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage 3B/4 nonsquamous non-small cell lung cancer (NSCLC): analysis of safety and activity of the FALCON trial. J Clin Oncol 29:2011
    • (2011) J Clin Oncol , vol.29 , pp. 2011
    • Garon, E.B.1    Kabbinavar, F.F.2    Neidhart, J.A.3    Neidhart, J.D.4    Gabrail, N.Y.5    Oliveira, M.R.6    Lu, S.7    Balkissoon, J.8
  • 191
    • 0031016945 scopus 로고    scopus 로고
    • Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6- dimethylxanthenone-4-acetic acid
    • Pruijn FB, van Daalen M, Holford NH, Wilson WR (1997) Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6- dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 39(6):541-546
    • (1997) Cancer Chemother Pharmacol , vol.39 , Issue.6 , pp. 541-546
    • Pruijn, F.B.1    Van Daalen, M.2    Holford, N.H.3    Wilson, W.R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.